EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Advancements and challenges in antifungal therapeutic development

Emily Puumala iD, Sara Fallah iD, Nicole Robbins iD, Leah E Cowen iD

Clinical Microbiology Reviews · 14.03.2024 · 37 (1)

DOI: 10.1128/cmr.00142-23 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 14.03.2024. Verfasst von Emily Puumala und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Antifungal Agents, Mycoses. Die Arbeit wurde bisher 123-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Gouvernement du Canada | Canadian Institutes of Health Research, HHS | National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over recent decades, the global burden of fungal disease has expanded dramatically. It is estimated that fungal disease kills approximately 1.5 million individuals annually; however, the true worldwide burden of fungal infection is thought to be higher due to existing gaps in diagnostics and clinical understanding of mycotic disease. The development of resistance to antifungals across diverse pathogenic fungal genera is an increasingly common and devastating phenomenon due to the dearth of available antifungal classes. These factors necessitate a coordinated response by researchers, clinicians, public health agencies, and the pharmaceutical industry to develop new antifungal strategies, as the burden of fungal disease continues to grow. This review provides a comprehensive overview of the new antifungal therapeutics currently in clinical trials, highlighting their spectra of activity and progress toward clinical implementation. We also profile up-and-coming intracellular proteins and pathways primed for the development of novel antifungals targeting their activity. Ultimately, we aim to emphasize the importance of increased investment into antifungal therapeutics in the current continually evolving landscape of infectious disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsMycosesHumansDrug Resistance, Fungal

Stichwörter der Autor:innen

AspergillusCandidaCryptococcusantifungalclinical therapeuticsclinical trialsdrug developmentdrug resistance mechanismsfungal pathogen

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Emily Puumala, Sara Fallah, Nicole Robbins, Leah E Cowen

Förderung

  • NIAID NIH HHS
  • Gouvernement du Canada | Canadian Institutes of Health Research
  • HHS | National Institutes of Health

Zitieren

APA

Puumala, E., Fallah, S., Robbins, N., & Cowen, L. E. (2024). Advancements and challenges in antifungal therapeutic development. Clinical Microbiology Reviews, 37(1). https://doi.org/10.1128/cmr.00142-23

Vancouver

Puumala E, Fallah S, Robbins N, Cowen LE. Advancements and challenges in antifungal therapeutic development. Clinical Microbiology Reviews. 2024;37(1). doi:10.1128/cmr.00142-23

BibTeX
@article{Puumala2024,
  author = {Puumala, Emily and Fallah, Sara and Robbins, Nicole and Cowen, Leah E},
  title = {Advancements and challenges in antifungal therapeutic development},
  journal = {Clinical Microbiology Reviews},
  year = {2024},
  volume = {37},
  number = {1},
  doi = {10.1128/cmr.00142-23}
}
Kostenlos starten →